Insider trading

Period: 120 months Stock: CYTK Minimum amount: $1M × + Add filter Clear all
Views & alerts

Save your view. Keep the filter you have built, and get an email when a new filing matches it. A free account does both.

When

Period

How far back the list reaches. Filings arrive days after the trade, so the newest rows always lag a little.

44 decisions over 120 months
Who

Role

The position the person holds at the company, read from the title on the filing. A chief executive who is also a director counts as the chief executive.

44 decisions over 120 months
The trade

Type of trade

Purchases, sales, or cluster buys: companies where 3 or more insiders bought within 30 days. The number beside each is what that choice would give.

44 decisions over 120 months
The trade

Minimum amount

Hides rows under this value. The amount is the shares traded times the price on the filing.

44 decisions over 120 months Remove this filter
The trade

Plan

  • Discretionary: they chose to sell that week.
  • Scheduled: a 10b5-1 plan fixed the sale months in advance, so the timing says nothing about what they knew.
  • Not stated: filed before the SEC added the box in April 2023, which is most of the older half of this database.
44 decisions over 120 months
The trade

Share of their own holding

How much of what they already held the trade moved. Selling a tenth of a stake is not the same act as selling all of it.

At least
44 decisions over 120 months
Ownership

What the chief executive holds

The value of the chief executive’s stock measured against base salary. The salary comes from the company’s own proxy. Companies with no figure are in neither direction.

44 decisions over 120 months
Stock
Insider
Type ?
Why it stands out
15 Sep 2026
Blum Robert I President & CEO · indirect
Sold on a plan
$6.79M 97,926 at 69.33
100%
Sold half or more
30 Jul 2026
Callos Andrew EVP, Chief Commercial Officer
Sold on a plan
$1.12M 14,000 at 79.88
19.3%
Planned (10b5-1)
1 Jul 2026
Callos Andrew EVP, Chief Commercial Officer
Sold on a plan
$1.29M 15,000 at 85.80
20.4%
Planned (10b5-1)
24 Jun 2026
Lee Sung EVP, Chief Financial Officer
Sold on a plan
$3.19M 38,730 at 82.30
38.0%
Planned (10b5-1)
1 Jun 2026
Callos Andrew EVP, Chief Commercial Officer
Sold on a plan
$1.11M 15,000 at 74.08
20.4%
Planned (10b5-1)
5 May 2026
Lee Sung EVP, Chief Financial Officer
Sold on a plan
$1.84M 23,906 at 76.87
27.4%
Planned (10b5-1)
5 May 2026
HENDERSON JOHN T Director
Sold on a plan
$1.52M 20,000 at 75.97
21.0%
Planned (10b5-1)
1 May 2026
Callos Andrew EVP, Chief Commercial Officer
Sold on a plan
$1.03M 15,857 at 65.00
21.3%
Planned (10b5-1)
17 Mar 2026
Blum Robert I President & CEO
Sold at will 2×
$2.27M 36,601 at 62.15
7.8%
Not planned
5 Mar 2026
Callos Andrew EVP, Chief Commercial Officer
Sold on a plan 2×
$1.61M 26,000 at 61.87
34.0%
Planned (10b5-1)
22 Dec 2025
WIERENGA WENDELL Director
Sold on a plan
$1.32M 20,000 at 66.14
38.1%
Planned (10b5-1)
5 Dec 2025
Callos Andrew EVP, Chief Commercial Officer
Sold on a plan
$3.46M 52,486 at 65.95
50.9%
Sold half or more
1 Dec 2025
Sold on a plan
$1.87M 28,064 at 66.72
73.8%
Sold half or more
17 Mar 2025
Blum Robert I President & CEO
Sold on a plan 2×
$1.68M 37,648 at 44.56
10.3%
Planned (10b5-1)
17 Mar 2025
Callos Andrew EVP, Chief Commercial Officer
Sold on a plan 2×
$1.07M 23,675 at 45.05
40.4%
Planned (10b5-1)
13 Mar 2025
Callos Andrew EVP, Chief Commercial Officer
Sold on a plan
$1.17M 26,771 at 43.62
41.5%
Planned (10b5-1)
5 Mar 2025
Blum Robert I President & CEO
Sold on a plan
$1.08M 25,000 at 43.23
6.2%
Planned (10b5-1)
17 Jun 2024
Blum Robert I President & CEO
Sold on a plan 2×
$1.18M 22,500 at 52.60
5.1%
Planned (10b5-1)
4 Jun 2024
Blum Robert I President & CEO
Sold on a plan
$1.10M 22,500 at 48.85
4.9%
Planned (10b5-1)
7 May 2024
Malik Fady Ibraham EVP Research & Development
Sold on a plan 2×
$1.01M 15,547 at 65.11
10.2%
Planned (10b5-1)
9 Apr 2024
Malik Fady Ibraham EVP Research & Development
Sold on a plan 2×
$2.42M 32,605 at 74.31
19.0%
Planned (10b5-1)
5 Mar 2024
Malik Fady Ibraham EVP Research & Development
Sold on a plan 2×
$2.20M 32,604 at 67.56
19.0%
Planned (10b5-1)
6 Feb 2024
Malik Fady Ibraham EVP Research & Development
Sold on a plan 2×
$2.59M 32,605 at 79.30
18.6%
Planned (10b5-1)
19 Jan 2024
Blum Robert I President & CEO
Sold on a plan
$1.02M 12,500 at 81.42
2.8%
Planned (10b5-1)
4 Jan 2024
Malik Fady Ibraham EVP Research & Development
Sold on a plan 2×
$1.36M 15,678 at 86.98
9.6%
Planned (10b5-1)
2 Jan 2024
Blum Robert I President & CEO
Sold on a plan
$1.06M 12,500 at 85.08
2.8%
Planned (10b5-1)
13 Oct 2022
Malik Fady Ibraham EVP Research & Development
Sold, plan not stated
$1.02M 21,513 at 47.28
11.3%
12 Sep 2022
HENDERSON JOHN T Director
Sold, plan not stated 3×
$1.20M 21,759 at 54.94
47.5%
8 Sep 2022
Malik Fady Ibraham EVP Research & Development
Sold, plan not stated
$1.12M 21,500 at 51.88
11.3%
1 Sep 2022
PARSHALL B LYNNE Director
Sold, plan not stated
$1.60M 30,296 at 52.79
75.2%
Sold half or more
10 Mar 2022
Malik Fady Ibraham EVP Research & Development
Sold, plan not stated
$1.02M 26,852 at 37.82
13.8%
27 Dec 2021
SMITH SANDFORD D Director
Sold, plan not stated 3×
$1.30M 28,290 at 45.79
80.7%
Sold half or more
9 Dec 2021
Malik Fady Ibraham EVP Research & Development
Sold, plan not stated 2×
$1.06M 29,166 at 36.49
16.3%
19 Nov 2021
SMITH SANDFORD D Director
Sold, plan not stated 3×
$1.20M 29,032 at 41.21
81.1%
Sold half or more
9 Nov 2021
Cragg David Chief HR & Admin Officer
Sold, plan not stated 2×
$1.88M 45,000 at 41.76
24.5%
8 Nov 2021
GAGE L PATRICK Director
Sold, plan not stated 2×
$1.09M 26,468 at 41.33
47.8%
5 Nov 2021
PARSHALL B LYNNE Director
Sold, plan not stated 4×
$1.24M 30,996 at 40.00
86.1%
Sold half or more
19 Oct 2021
Jaw Ching SVP Finance & CFO
Sold, plan not stated
$1.28M 35,687 at 35.73
40.2%
9 Dec 2020
BVF PARTNERS L P/IL See Explanaton of Responses
Sold, plan not stated 3×
$7.76M 430,954 at 18.00
48.2%
5 Oct 2020
PARSHALL B LYNNE Director
Sold, plan not stated 4×
$1.51M 50,311 at 30.00
100%
Sold half or more
13 Feb 2020
Sold, plan not stated 3×
$16.92M 1,072,030 at 15.79
71.6%
Sold half or more
11 Dec 2019
Bought 3×
$1.13M 118,413 at 9.52
3.4%
First buy on file
10 Dec 2019
Bought 3×
$2.10M 223,659 at 9.40
6.7%
First buy on file
31 Aug 2017
Morgan Bradley Paul SVP Drug Discovery & Early Dev
Sold, plan not stated 15×
$1.77M 118,330 at 15.00
71.8%
Sold half or more
Showing 1–44 of 44.